Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - ThermoGenesis Holdings, Inc. | ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ThermoGenesis Holdings, Inc. | ex31-1.htm |
| 10-Q - FORM 10-Q - ThermoGenesis Holdings, Inc. | kool20160930_10q.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Cesca Therapeutics Inc. (the "Company") on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission (the "Report"), we, Robin C. Stracey, Chief Executive Officer and Michael Bruch, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Dated: November 17, 2016 |
/s/ Dr. Xiaochun (Chris) Xu |
| |
|
|
|
Dr. Xiaochun (Chris) Xu |
|
|
|
|
Interim Chief Executive Officer |
|
| (Principal Executive Officer) | |||
| Dated: November 17, 2016 | /s/ Michael Bruch | ||
| Michael Bruch | |||
| Chief Financial Officer | |||
| (Principal Financial Officer and Principal Accounting Officer) |